 Advaxis, Inc. is a small clinical-stage biotechnology company developing oncological therapeutics with their live attenuated Listeria monocytogenes antigen-delivery platform technology. Advaxis is currently developing three internal therapeutic programs ADXS-503 Phase 12, ADXS-504 Phase 1 expected in 2Q 21, and ADXS-PSA Phase 12 for various oncology indications. 